Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?

Pharmaceuticals

Volumn 3, Issue 1, 2010, Pages

  Cravedi, Paolo ^a,b   Brusegan, Varusca ^a,b   Ruggenenti, Piero ^a,b   Campbell, Ruth ^c   Remuzzi, Giuseppe ^a,b  

^a Clinical Research Center for Rare Diseases 'Aldo e Cele Daccò'   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c University of Alabama at Birmingham   (United States)

Author keywords

Hyperkalemia; Idiopathic membranous nephropathy; Proteinuria; Spironolactone

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; PROTEIN; RAMIPRIL; SPIRONOLACTONE; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG RESPONSE; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPERKALEMIA; MALE; MAXIMUM TOLERATED DOSE; MEMBRANOUS GLOMERULONEPHRITIS; MORNING DOSAGE; NEPHROTIC SYNDROME; POTASSIUM BLOOD LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

EID: 77951926399     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3010001     Document Type: Article

References (18)

1. Hostetter, T.H.; Ibrahim, H.N. Aldosterone in chronic kidney and cardiac disease. J. Am. Soc. Nephrol. 2003, 14, 2395-2401.
2. Epstein, M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol. Dial. Transplant 2003, 18, 1984-1992.
3. Greene, E.L.; Kren, S.; Hostetter, T.H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 1996, 98, 1063-1068.
4. Quan, Z.Y.; Walser, M.; Hill, G.S. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992, 41, 326-333.
5. Rocha, R.; Chander, P.N.; Zuckerman, A.; Stier, C.T., Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33, 232-237.
6. Chrysostomou, A.; Becker, G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N. Engl. J. Med. 2001, 345, 925-926.
7. Rachmani, R.; Slavachevsky, I.; Amit, M.; Levi, Z.; Kedar, Y.; Berla, M.; Ravid, M. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet. Med. 2004, 21, 471-475.
8. Navaneethan, S.D.; Nigwekar, S.U.; Sehgal, A.R.; Strippoli, G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2009, 4, 542-551.
9. Ruggenenti, P.; Chiurchiu, C.; Brusegan, V.; Abbate, M.; Perna, A.; Filippi, C.; Remuzzi, G. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 2003, 14, 1851-1857.
10. Sato, A.; Saruta, T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J. Int. Med. Res. 2001, 29, 13-21.
11. Sato, A.; Hayashi, K.; Naruse, M.; Saruta, T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41, 64-68.
12. Epstein, M.; Williams, G.H.; Weinberger, M.; Lewin, A.; Krause, S.; Mukherjee, R.; Patni, R.; Beckerman, B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 2006, 1, 940-951.
13. Schjoedt, K.J.; Andersen, S.; Rossing, P.; Tarnow, L.; Parving, H.H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47, 1936-1939.
14. Navaneethan, S.D.; Nigwekar, S.U.; Sehgal, A.R.; Strippoli, G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev. 2009, CD007004.
15. Buter, H.; Hemmelder, M.H.; Navis, G.; de Jong, P.E.; de Zeeuw, D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol. Dial. Transplant 1998, 13, 1682-1685.
16. Schepkens, H.; Vanholder, R.; Billiouw, J.M.; Lameire, N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am. J. Med. 2001, 110, 438-441.
17. Juurlink, D.N.; Mamdani, M.M.; Lee, D.S.; Kopp, A.; Austin, P.C.; Laupacis, A.; Redelmeier, D.A. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004, 351, 543-551.
18. Cravedi, P.; Ruggenenti, P.; Remuzzi, G. Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr. Hypertens. Rep. 2007, 9, 430-436.